KB408
AXP000195.1 · Viral vector gene therapy
- Platform
- HSV-1 (replication-defective)
- Targets
- SERPINA1
- Originator
- Krystal Biotech
- Sponsor
- Krystal Biotech
Names
Virus
- Role
- In vivo gene transfer
- Family
- Herpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- non replicating
- Modifications
- replication-defective HSV-1 backbone; two copies of SERPINA1
- Transgenes
- SERPINA1
- Route
- inhaled
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06049082 | A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency | Recruiting | Phase 1 | 2024-02-15 | 2025-12 | 15 | Alpha 1-Antitrypsin Deficiency |
Recent changes
No changes recorded in its trials yet.
Notes
Nebulised (inhaled) replication-defective HSV-1 vector delivering two copies of SERPINA1 (normal human alpha-1 antitrypsin), for alpha-1 antitrypsin deficiency (PI*ZZ); phase 1 SERPENTINE-1, NCT06049082, first patient dosed February 2024. Route left empty because 'inhaled' is not in the route vocabulary.
How to cite
KB408 (AXP000195.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000195.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.